Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2025 | $134.00 → $145.00 | Buy | H.C. Wainwright |
| 5/29/2025 | $110.00 | Neutral | Goldman |
| 3/13/2025 | $145.00 | Buy | Citigroup |
| 1/10/2025 | $172.00 | Buy | Truist |
| 12/11/2024 | $170.00 | Overweight | Wells Fargo |
| 12/2/2024 | Outperform | BMO Capital Markets | |
| 11/19/2024 | $130.00 | Buy | Berenberg |
| 11/19/2024 | $110.00 → $125.00 | In-line → Outperform | Evercore ISI |
H.C. Wainwright reiterated coverage of BioNTech with a rating of Buy and set a new price target of $145.00 from $134.00 previously
Goldman initiated coverage of BioNTech with a rating of Neutral and set a new price target of $110.00
Citigroup initiated coverage of BioNTech with a rating of Buy and set a new price target of $145.00
LP.8.1 variant adapted COVID-19 vaccine COMIRNATY is now authorized in Canada for individuals 6 months of age and older. It is expected to be available in Canada in the coming weeks.KIRKLAND, QC, Aug. 18, 2025 /CNW/ - Pfizer Canada ULC and BioNTech SE (NASDAQ:BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 variant adapted COMIRNATY® COVID-19 vaccine for individuals aged 6 months and older. The updated COMIRNATY® vaccine targets the Omicron LP.8.1 variant, one of the most recently circulating SARS-CoV-2 lineages. This season's Pfizer and BioNTech C
Continued execution of BioNTech's oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antibody candidate targeting PD-L11 and VEGF-AEntered a global strategic co-development and co-commercialization collaboration with Bristol Myers Squibb ("BMS") to jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor typesAnnounced strategic transaction to acquire CureVac N.V. ("CureVac") to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidatesPresented multiple clinical update
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulationsUpon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and olderTo date, over a billion adults and children around the world have received the Pfizer-BioNTech COVID-19 vaccine, which continues to demonstrate a favorable safety and efficacy profile supported by extensive real-world evidence, clinical, non-clinical, pharmacovigilance and manufacturing dataDoses will be ready to sh
F-4 - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
6-K - BioNTech SE (0001776985) (Filer)
Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer ("CFO") effective July 1, 2025. He will join BioNTech from Novartis AG's global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his term on June 30, 2025. In his new role as CFO at BioNTech, Ramón Zapata will ensure the Company's financial direction continues to align with BioNTech's strategy to become a multi-product company i
Acquisition to support the global execution of BioNTech's oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumorsWith the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinationsBioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 202
MAINZ, Germany, October 31, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time (16:30 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S. On the day, BioNTech's leadership team will provide an overview of the Company's corporate strategy and clinical progress across its pipeline. Investors, analysts and the interested public are invited to join the event online via this link. A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company's website for one yea
Continued execution of BioNTech's oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antibody candidate targeting PD-L11 and VEGF-AEntered a global strategic co-development and co-commercialization collaboration with Bristol Myers Squibb ("BMS") to jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor typesAnnounced strategic transaction to acquire CureVac N.V. ("CureVac") to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidatesPresented multiple clinical update
MAINZ, Germany, July 21, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the second quarter 2025 on Monday, August 4, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via
Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies Presented multiple clinical updates across oncology pipeline underlining BioNTech's combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates ("ADCs") Development and commercial preparation for a 2025/2026 season variant-adapted COVID-19 vaccine First quarter 2025 revenues of €0.2 billion2, net loss of €0.4 billion and basic and diluted loss per share of €1.73 ($1.823) Maintained strong financial positio
SC 13G/A - BioNTech SE (0001776985) (Subject)
SC 13D - BioNTech SE (0001776985) (Filed by)
SC 13G/A - BioNTech SE (0001776985) (Subject)